The Evolving Role of Monoclonal Antibodies and Dendritic Cell Therapy in Hematologic Malignancies

References

• Carswell, E.A., Old, L.J., Kassel, R.L., et al. (1975) "An endotoxin-induced serum factor that causes necrosis of tumors", Proc. Natl Acad. Sci. USA 72, 3666–3670.
   PubMed Web of Science ®Google Scholar
• Kohler, G. and Milstein, C. (1975) "Continuous cultures of fused cells secreting antibody of predefined specificity", Nature 256, 495–497.
   PubMed Web of Science ®Google Scholar
• de Geus, B. and Hendriksen, C.F. (1998) "In vivo and in vitro production of monoclonal antibodies: current possibilities and future perspectives. Introduction", Res. Immunol. 149, 533–534.
   PubMedGoogle Scholar
• Kavanaugh, A.F., Davis, L.S., Nichols, L.A., et al. (1994) "Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1", Arthritis Rheu. 37, 992–999.
   PubMed Web of Science ®Google Scholar
• Topol, E.J., Califf, R.M., Weisman, H.F., et al. (1994) "Randomised trial of coronary intervention with antibody against platelet Itb/Bla integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators", Lancet 343, 881–886.
   PubMed Web of Science ®Google Scholar
• The IMpact-RSV Study Group (1998) "Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants", Pediatrics 102, 1–7.
   Web of Science ®Google Scholar
• Ghetie, M.A., Podar, E.M., Ilgen, A., et al. (1997) "Homo-dimerization of tumor-reactive monoclonal antibodies mark-edly increases their ability to induce growth arrest or apoptosis of tumor cells", Proc. Natl Acad. Sci. USA 94, 7509–7514.
   PubMed Web of Science ®Google Scholar
• Trauth, B.C., Klas, C., Peters, A.M., et al. (1989) "Monoclonal antibody-mediated tumor regression by induction of apop-tosis", Science 245, 301–305.
   PubMed Web of Science ®Google Scholar
• Dillman, R.O., Beauregard, J.C., Halpern, S.E. and Clutter, M. (1986) "Toxicities and side effects associated with intravenous infusions of murine monoclonal antibodies", J. Biol. Response Modif. 5, 73–84.
   PubMedGoogle Scholar
• Breedveld, F.C. (2000) "Therapeutic monoclonal antibodies", Lancet 355, 735–740, (Review, 33 refs).
   PubMed Web of Science ®Google Scholar
• Jain, R.K. (1987) "Transport of molecules across tumor vasculature", Cancer Metastasis Rev. 6, 559–593, (Review, 196 refs).
   PubMed Web of Science ®Google Scholar
• Vaswani, S.K. and Hamilton, R.G. (1998) "Humanized antibodies as potential therapeutic drugs", Ann. Allergy, Asthma, Immunol. 81, 105–115, (Review, 102 refs).
   PubMed Web of Science ®Google Scholar
• Nadler, L.M., Stashenko, P., Hardy, R., et al. (1980) "Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen", Cancer Res. 40, 3147–3154.
   PubMed Web of Science ®Google Scholar
• Brown, S.L., Miller, R.A., Horning, S.J., et al. (1989) "Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon", Blood 73, 651–661.
   PubMed Web of Science ®Google Scholar
• Bernstein, ID., Singer, J.W., Smith, F.O., et al. (1992) "Differences in the frequency of normal and clonal precursors of colony-forming cells in chronic myelogenous leukemia and acute myelogenous leukemia", Blood 79, 1811–1816.
   PubMed Web of Science ®Google Scholar
• McGraw, K.J., Rosenblum, M.G., Cheung, L. and Scheinberg, D.A. (1994) "Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias", Cancer Immunol., Immunother. 39, 367–374.
   PubMed Web of Science ®Google Scholar
• Caron, P.C., Jurcic, J.G., Scott, A.M., et al. (1994) "A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogeni-city", Blood 83, 1760–1768.
   PubMed Web of Science ®Google Scholar
• Jurcic, J.G., DeBlasio, T., Dumont, L., et al. (2000) "Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia", Clin. Cancer Res. 6, 372–380.
   PubMed Web of Science ®Google Scholar
• Hinman, L.M., Hamann, P.R., Wallace, R., et al. (1993) "Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics", Cancer Res. 53(14), 3336–3342.
   PubMed Web of Science ®Google Scholar
• Sievers, E.L., Appelbaum, ER., Spielberger, R.T., et al. (1999) "Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate", Blood 93(11), 3678–3684.
   PubMed Web of Science ®Google Scholar
• Sievers, E.L., Larson, R.A., Stadtmauer, E.A., et al. (2001) "Mylotarg Study Group: Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse", J. Clin. Oncol. 19(13), 3244–3254.
   PubMed Web of Science ®Google Scholar
• Schwartz, MA., Lovett, D.R. and Redner, A. (1993) "Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias", J. Clin. Oncol. 11(2), 294–303.
   PubMed Web of Science ®Google Scholar
• Jurcic, J.G., McDevitt, M.R., Sgouros, G., et al. (1999) "Phase I trial of targeted alpha-particle therapy for myeloid leukemias with Bismuth-213-Hu1v1195 (ANTI-CD33)", Proc. Annu. Meet Am. Soc. Clin. Oncol., 18.
   Google Scholar
• Appelbaum, F.R., Matthews, D.C., Eary, J.F., et al., (1992) "The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia", Transplantation 54(5), 829–833.
   PubMed Web of Science ®Google Scholar
• Matthews, D.C., Appelbaum, ER., Eary, J.F., et al. (1995) "Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclo-phosphamide and total body irradiation", Blood 85(4), 1122–1131.
   PubMed Web of Science ®Google Scholar
• Miller, R.A., Maloney, D.G., Warnke, R. and Levy, R. (1982) "Treatment of b-cell lymphoma with monoclonal anti-idiotype antibody", N. Engl. J. Med. 306, 517–522.
   PubMed Web of Science ®Google Scholar
• Meeker, T.C., Lowder, J., Maloney, D.G., et al. (1985) "A clinical trial of anti-idiotype therapy for B cell malignancy", Blood 65(6), 1349–1363.
   PubMed Web of Science ®Google Scholar
• McLaughlin, P., White, CA., Grillo-Lopez, A.J. and Maloney, D.G. (1998) "Clinical status and optimal use of rituximab for B-cell lymphomas", Oncology (Huntington) 12(12), 1763–1769, (Review, 16 refs). See discussion on 1769–1770 and 1775–1777.
   PubMed Web of Science ®Google Scholar
• Maloney, D.G., Liles, TM., Czerwinski, D.K., et al. (1994) "Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma", Blood 84(8), 2457–2466.
   PubMed Web of Science ®Google Scholar
• Foran, J.M., Gupta, R.K., Cunningham, D., et al. (2000) "A UK multicentre phase 11 study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response", Br. J. Haematol. 109(1), 81–88.
   PubMed Web of Science ®Google Scholar
• Czuczman, MS., Grillo-Lopez, A.J., McLaughlin, P., et al. (2001) "Clearing of cells bearing the bc1-2 [t(14;18)] transloca-tion from blood and marrow of patients treated with Rituximab alone or in combination with CHOP chemother-apy", Ann. Oncol. 12(1), 109–114.
   PubMed Web of Science ®Google Scholar
• Coiffier, B., Haioun, C., Ketterer, N., et al. (1998) "Rituximab (anti-CD20 monoclonal antibody) for the treat-ment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase 11 study", Blood 92(6), 1927–1932.
   PubMed Web of Science ®Google Scholar
• Kuehnle, I., Huls, M.H., Liu, Z., et al. (2000) "CD20 monoclonal antibody (rituximab) for therapy of Epstein—Barr virus lymphoma after hemopoietic stem-cell transplan-tation", Blood 95(4), 1502–1505.
   PubMed Web of Science ®Google Scholar
• Dyer, M.J., Hale, G., Hayhoe, F.G. and Waldmann, H. (1989) "Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype", Blood 73(6), 1431–1439.
   PubMed Web of Science ®Google Scholar
• Dyer, M.J., Kelsey, S.M., Mackay, H.J., et al. (1997) "In vivo purging of residual disease in CLL with Campath-1H", Br. J. Haematol. 97(3), 669–672.
   PubMed Web of Science ®Google Scholar
• Pawson, R., Dyer, M.J., Barge, R., et al. (1997) "Treatment of T-cell prolymphocytic leukemia with human CD52 antibody", J. Clin. Oncol. 15(7), 2667–2672.
   PubMed Web of Science ®Google Scholar
• Grossbard, Mi., Lambert, J.M., Goldmacher, VS., et al. (1993) "Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms", J. Clin. Oncol. 11(4), 726–737.
   PubMed Web of Science ®Google Scholar
• Kaminski, MS., Zasadny, KR., Francis, I.R., et al. (1996) "Iodine-131-anti-B1 radioimmunotherapy for B-cell lym-phoma", J. Clin. Oncol. 14(7), 1974–1981.
   PubMed Web of Science ®Google Scholar
• Olweus, J., BitMansour, A., Warnke, R., et al. (1997) "Dendritic cell ontogeny: a human dendritic cell lineage of myeloid origin", Proc. Natl Acad. Sci. USA 94, 12551–12556.
   PubMed Web of Science ®Google Scholar
• Szabolcs, P., Avigan, D., Gezelter, S., et al. (1996) "Dendritic cells and macrophages can mature independently from a human bone marrow-derived, post-colony-forming unit intermediate", Blood 87, 4520–4530.
   PubMed Web of Science ®Google Scholar
• Galy, A., Travis, M., Cen, D., et al. (1995) "Human T.B. natural killer, and dendritic cells arise from a common bone marrow progenitor cell subset", Immunity 3, 459–473.
   PubMed Web of Science ®Google Scholar
• Ardavin, C. (1997) "Thymic dendritic cells", Immunol. Today 18, 350–361, (Review, 95 refs).
   PubMedGoogle Scholar
• Fairchild, P.J. and Austyn, J.M. (1990) "Thymic dendritic cells: phenotype and function", Int. Rev. Immunol. 6, 187–196, (Review, 92 refs).
   PubMedGoogle Scholar
• Steinman, R.M. and Swanson, J. (1995) "The endocytic activity of dendritic cells", J. Exp. Med. 182,283–288, (Review, 62 refs).
   PubMed Web of Science ®Google Scholar
• Prickett, T.C., McKenzie, J.L. and Hart, D.N. (1992) "Adhesion molecules on human tonsil dendritic cells", Transplantation 53, 483–490.
   PubMed Web of Science ®Google Scholar
• Starling, G.C., McLellan, AD., Egner, W., et al. (1995) "Intercellular adhesion molecule-3 is the predominant co-stimulatory ligand for leukocyte function antigen-1 on human blood dendritic cells", Eur. J. Immunol. 25, 2528–2532.
   PubMed Web of Science ®Google Scholar
• Schwartz, R.H. (1990) "A cell culture model for T lymphocyte clonal anergy", Science 248, 1349–1356.
   PubMed Web of Science ®Google Scholar
• Guinan, E.C., Gribben, J.G., Boussiotis, V.A., et al. (1994) "Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity", Blood 84, 3261–3282, (Review, 244 refs).
   PubMed Web of Science ®Google Scholar
• McLellan, A.D., Sorg, R.V., Williams, L.A. and Hart, D.N. (1996) "Human dendritic cells activate T lymphocytes via a CD40: CD40 ligand-dependent pathway", Fur. J. Immunol. 26, 1204–1210.
   Web of Science ®Google Scholar
• Caux, C., Massacrier, C., Vanbervliet, B., et al. (1994) "Activation of human dendritic cells through CD40 cross-linking", J. Exp. Med. 180, 1263–1272.
   PubMed Web of Science ®Google Scholar
• Cella, M., Scheidegger, D., Palmer-Lehmann, K., et al. (1996) "Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T—T help via APC activation", J. Exp. Med. 184, 747–752.
   PubMed Web of Science ®Google Scholar
• Fernandez, N., Lozier, A., Flament, C., et al. (1999) "Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo", Nat. Med. 5(4), 405–411.
   PubMed Web of Science ®Google Scholar
• Grabbe, S., Bruvers, S., Gab, R.L., et al. (1991) "Tumor antigen presentation by murine epidermal cells", J. Immunol. 146, 3656–3661.
   PubMed Web of Science ®Google Scholar
• Grabbe, S., Bruvers, S., Lindgren, A.M., et al. (1992) "Tumor antigen presentation by epidermal antigen-presenting cells in the mouse: modulation by granulocyte-macrophage colony-stimulating factor, tumor necrosis factor alpha, and ultra-violet radiation", J. Leukoc. Biol. 52, 209–217.
   PubMed Web of Science ®Google Scholar
• Williams, L.A., Egner, W. and Hart, D.N. (1994) "Isolation and function of human dendritic cells", Int. Rev. Cytol. 153, 41–103, (Review, 228 refs).
   PubMed Web of Science ®Google Scholar
• Fearnley, D.B., McLellan, A.D., Mannering, S.I., et al. (1997) "Isolation of human blood dendritic cells using the CMRF-44 monoclonal antibody: implications for studies on antigen-presenting cell function and immunotherapy", Blood 89, 3708–3716.
   PubMed Web of Science ®Google Scholar
• Zhou, L.J. and Tedder, T.F. (1995) "Human blood dendritic cells selectively express CD83, a member of the immunoglo-bulin superfamily", J. Immunol. 154, 3821–3835.
   PubMed Web of Science ®Google Scholar
• Bernhard, H., Disis, M.L., Heimfeld, S., et al. (1995) "Generation of immunostimulatory dendritic cells from human CD34 + hematopoietic progenitor cells of the bone marrow and peripheral blood", Cancer Res. 55, 1099–1104.
   PubMed Web of Science ®Google Scholar
• Romani, N., Gruner, S., Brang, D., et al. (1994) "Proliferating dendritic cell progenitors in human blood", J. Exp. Med. 180, 83–93.
   PubMed Web of Science ®Google Scholar
• Veelken, H. (2000) "Stimulation of cytotoxic T-cells against idiotype immunoglobulin of malignant lymphoma with protein-pulsed or idiotype-transuded dendritic cells", Blood 95(4), 1342–1349.
   PubMed Web of Science ®Google Scholar
• Chen, L., Linsley, P.S. and Hellstrom, K.E. (1993) "Costimula-tion of T cells for tumor immunity", Immunol. Today 14, 483–486, (Review, 24 refs).
   PubMedGoogle Scholar
• Gimmi, C.D., Freeman, G.J., Gribben, J.G., et al. (1993) "Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation", Proc. Natl Acad. Sci. USA 90, 6586–6590.
   PubMed Web of Science ®Google Scholar
• Simon, J.C., Tigelaar, R.E., Bergstresser, P.R., et al. (1991) "Ultraviolet B radiation converts Langerhans cells from immunogenic to tolerogenic antigen-presenting cells. Induc-tion of specific clonal anergy in CD4 + T helper 1 cells", J. Immunol. 146, 485–491.
   PubMed Web of Science ®Google Scholar
• Muller, H.K., Bucana, C. and Kripke, M.L. (1992) "Antigen presentation in the skin: modulation by U.V. radiation and chemical carcinogens", Semin. Immunol. 4, 205–215, (Review, 68 refs).
   PubMedGoogle Scholar
• Matteo, R.G., Howard, J., Buggins, A., et al. (1999) "Phenotypic and functional characteristics of monocyte-derived dendritic cells from patients with myelodysplastic syndromes", Br. J. Haematol. 107, 844–850.
   PubMed Web of Science ®Google Scholar
• Hart, D.N. (1997) "Dendritic cells: unique leukocyte populations which control the primary immune response", Blood 90, 3245–3287, (Review, 545 refs).
   PubMed Web of Science ®Google Scholar
• Nieda, M., Nicol, A., Kikuchi, A., et al. (1998) "Dendritic cells stimulate the expansion of bcr—abl specific CD8 + T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia", Blood 91, 977–983.
   PubMed Web of Science ®Google Scholar
• Paglia, P., Chiodoni, C., Rodolfo, M. and Colombo, M.P. (1996) "Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo", J. Exp. Med. 183, 317–322.
   PubMed Web of Science ®Google Scholar
• Lespagnard, L., Mettens, P., Verheyden, A.M., et al. (1998) "Dendritic cells fused with mastocytoma cells elicit thera-peutic antitumor immunity", Int. J. Cancer 76, 250–258.
   PubMed Web of Science ®Google Scholar
• Gong, J., Chen, D., Kashiwaba, M. and Kufe, D. (1997) "Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells", Nat. Med. 3, 558–561.
   PubMed Web of Science ®Google Scholar
• Choudhury, A., Gajewski, J.L., Liang, J.C., et al. (1997) "Use of leukemic dendritic cells for the generation of antileu-kemic cellular cytotoxicity against Philadelphia chromo-some-positive chronic myelogenous leukemia", Blood 89, 1133–1142.
   PubMed Web of Science ®Google Scholar
• Dietz, A.B. and Vuk-Pavlovic, S. (1998) "High efficiency adenovirus-mediated gene transfer to human dendritic cells", Blood 91, 392–398.
   PubMed Web of Science ®Google Scholar
• Reeves, M.E., Royal, R.E., Lam, J.S., Rosenberg, S.A. and Hwu, P. (1996) "Retroviral transduction of human dendritic cells with a tumor-associated antigen gene", Cancer Res. 56, 5672–5677.
   PubMed Web of Science ®Google Scholar
• Hsu, F.J., Benike, C., Fagnoni, F., et al. (1996) "Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells", Nat. Med. 2, 52–58.
   PubMed Web of Science ®Google Scholar
• Fujii, S., Shimizu, K., Fujimoto, K., et al. (1999) "Analysis of a chronic myelogenous leukemia patient vaccinated with leukemic dendritic cells following autologous peripheral blood stem cell transplantation", Jpn J. Cancer Res. 90, 1117–1129.
   PubMedGoogle Scholar